Recurrent Respiratory Papillomatosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports
The latest healthcare forecast report provides an in-depth analysis of Recurrent Respiratory Papillomatosis, offering comprehensive insights into the Recurrent Respiratory Papillomatosis revenue trends, prevalence, and treatment landscape. The report delves into key Recurrent Respiratory Papillomatosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Recurrent Respiratory Papillomatosis therapies. Additionally, we cover the landscape of Recurrent Respiratory Papillomatosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Recurrent Respiratory Papillomatosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Recurrent Respiratory Papillomatosis space.
Some of the key facts of the Recurrent Respiratory Papillomatosis Market Report:
The Recurrent Respiratory Papillomatosis market size was valued ~USD 10.26 million in 2023 and is anticipated to grow with a significant CAGR of 39.9% during the study period (2020-2034)
In February 2025, INOVIO (NASDAQ: INO), a biotechnology company focused on developing DNA medicines for HPV-related conditions, cancer, and infectious diseases, announced that peer-reviewed results from its Phase 1/2 trial of INO-3107 for recurrent respiratory papillomatosis (RRP) have been published in Nature Communications. The study, titled DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107, revealed that INO-3107 stimulated new T cell populations in the blood that migrated to the airway and papilloma tissues, correlating with fewer surgeries post-treatment. Of the 32 patients enrolled, 26 (81%) needed fewer surgical interventions after treatment compared to the year before. The therapy was also well tolerated. INOVIO intends to submit a Biologics License Application (BLA) for INO-3107 by mid-2025 and will seek rolling submission and priority review through the FDA's accelerated approval pathway. If approved, INO-3107 would become the first DNA-based medicine approved for any condition in the U.S.
In December 2024, Precigen, Inc. announced that it has completed the submission of its biologics license application (BLA) to the FDA for PRGN-2012 (zopapogene imadenovec†) as a treatment for adult recurrent respiratory papillomatosis (RRP).
In August 2024, Precigen announced a strategic shift to concentrate on the potential commercialization of PRGN-2012. As part of this realignment, the company will reduce its workforce by 20% and halt all preclinical programs. This decision highlights Precigen's dedication to advancing PRGN-2012 and reallocating resources to enhance its commercial potential.
The EU4 and the UK represented about 16% of the 7MM market size, with the RRP market valued at approximately USD 1.66 million in 2023.
In 2023, Germany had the largest market size for RRP among the EU countries, reaching nearly USD 0.45 million, whereas Spain had the smallest market size, approximately USD 0.25 million.
The overall market size of RRP is expected to increase during the forecast period, driven by the anticipated introduction of emerging therapies such as INO-3107, PRGN-2012, and others.
Key Recurrent Respiratory Papillomatosis Companies: Precigen, Inc., Inovio Pharmaceuticals, and others
Key Recurrent Respiratory Papillomatosis Therapies: PRGN-2012, INO-3107, and others
The Recurrent Respiratory Papillomatosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Recurrent Respiratory Papillomatosis pipeline products will significantly revolutionize the Recurrent Respiratory Papillomatosis market dynamics.
The total number of diagnosed prevalent cases of RRP in the US was approximately 16,980 in 2023 and is expected to rise during the forecast period.
According to DelveInsight's estimates, the US has the highest number of diagnosed prevalent cases of RRP among the 7MM, followed by the EU4 and the UK, with Japan contributing to 24% and 10% of all RRP cases, respectively.
In 2023, Japan reported the highest number of RRP cases in adults aged 18 and older (~2,400), followed by adolescents aged 9-17 years (~50). The fewest cases were observed in children aged 0-8 years, with a total of approximately 25.
In 2023, the EU4 and the UK reported a total of approximately 6,240 diagnosed prevalent cases of RRP, with around 5,740 cases linked to HPV 6 and/or HPV 11, and about 500 cases associated with other high-risk subtypes such as HPV-16, 18, 31, 33, and 39. The large number of cases related to HPV 6 and 11 highlights the dominant role these strains play in RRP, as they are the primary causative agents.
In 2023, Germany reported the highest number of diagnosed prevalent RRP cases among the EU4 and the UK, with nearly 1,684 cases. France followed with around 1,370 cases, Italy had approximately 1,220, the UK reported about 1,022, and Spain had the lowest with roughly 944 cases. This distribution underscores the differing disease burden across European countries.
Recurrent Respiratory Papillomatosis Overview
Recurrent Respiratory Papillomatosis (RRP) is a rare condition characterized by the growth of benign tumors, called papillomas, in the airways, primarily affecting the larynx, trachea, and bronchi. These growths are caused by infection with the human papillomavirus (HPV), particularly types 6 and 11. RRP can lead to airway obstruction, hoarseness, breathing difficulties, and recurrent infections. The condition is chronic, often requiring repeated surgical interventions to remove the papillomas. It can occur in both children (juvenile-onset RRP) and adults (adult-onset RRP), with varying severity and progression.
Recurrent Respiratory Papillomatosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Recurrent Respiratory Papillomatosis Epidemiology Segmentation:
The Recurrent Respiratory Papillomatosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Recurrent Respiratory Papillomatosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Recurrent Respiratory Papillomatosis market or expected to get launched during the study period. The analysis covers Recurrent Respiratory Papillomatosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Recurrent Respiratory Papillomatosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Recurrent Respiratory Papillomatosis Market Drivers
Increasing Incidence of HPV Infections
Advancements in Surgical and Therapeutic Options
Rising Awareness and Early Diagnosis
Improved Treatment Modalities
Research and Development Investments
Recurrent Respiratory Papillomatosis Market Barriers
Limited Awareness and Diagnosis
Lack of Cure
High Treatment Costs
Fragmented Treatment Landscape
Limited Availability of Effective Therapies
Challenges in HPV Vaccination Implementation
Scope of the Recurrent Respiratory Papillomatosis Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Recurrent Respiratory Papillomatosis Companies: Precigen, Inc., Inovio Pharmaceuticals, and others
Key Recurrent Respiratory Papillomatosis Therapies: PRGN-2012, INO-3107, and others
Recurrent Respiratory Papillomatosis Therapeutic Assessment: Recurrent Respiratory Papillomatosis current marketed and Recurrent Respiratory Papillomatosis emerging therapies
Recurrent Respiratory Papillomatosis Market Dynamics: Recurrent Respiratory Papillomatosis market drivers and Recurrent Respiratory Papillomatosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Recurrent Respiratory Papillomatosis Unmet Needs, KOL's views, Analyst's views, Recurrent Respiratory Papillomatosis Market Access and Reimbursement
Table of Contents
1. Recurrent Respiratory Papillomatosis Market Report Introduction
2. Executive Summary for Recurrent Respiratory Papillomatosis
3. SWOT analysis of Recurrent Respiratory Papillomatosis
4. Recurrent Respiratory Papillomatosis Patient Share (%) Overview at a Glance
5. Recurrent Respiratory Papillomatosis Market Overview at a Glance
6. Recurrent Respiratory Papillomatosis Disease Background and Overview
7. Recurrent Respiratory Papillomatosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Recurrent Respiratory Papillomatosis
9. Recurrent Respiratory Papillomatosis Current Treatment and Medical Practices
10. Recurrent Respiratory Papillomatosis Unmet Needs
11. Recurrent Respiratory Papillomatosis Emerging Therapies
12. Recurrent Respiratory Papillomatosis Market Outlook
13. Country-Wise Recurrent Respiratory Papillomatosis Market Analysis (2020–2034)
14. Recurrent Respiratory Papillomatosis Market Access and Reimbursement of Therapies
15. Recurrent Respiratory Papillomatosis Market Drivers
16. Recurrent Respiratory Papillomatosis Market Barriers
17. Recurrent Respiratory Papillomatosis Appendix
18. Recurrent Respiratory Papillomatosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
2 hours ago
- CBC
Medevac delays put Nunavik patients at risk, say doctors
A lack of medevac flights is putting patients at risk in northern Québec, say doctors in the region. "I witnessed a lot of pretty bad situations linked with the lack of pilots and planes," says Vincent Rochette-Coulombe, a general practitioner at the Inuulitsivik Health Centre in Puvirnituq. The health centre serves as a hub for the seven Nunavik villages along the Hudson Bay coast. Every day, Rochette-Coulombe and his colleagues take in some of the sickest patients from that area, flown in by bush plane. Many need to be stabilized and then are flown further to Montreal for emergency care. However, air travel in and out of Pivurnituq has been made that much more difficult due to ongoing renovations to the community's runway. Those renovations mean only bush planes such as Twin Otters — smaller, slower aircraft — can land there at this time. The situation came to a head last week when one night the health centre team received calls to prepare to take in a premature baby and a patient with an abdominal hemorrhage, coming from separate villages. But Rochette-Coulombe said there weren't enough aircraft available. Ultimately, a plane needed to be dispatched from Kuujjuaq to take one of the patients back to that health centre. On another night, a baby in respiratory distress and "near death," according to Rochette-Coulombe, arrived at the health centre at 2 a.m. The baby needed to be medevaced but the flight was delayed by three or four hours due to pilot availability, he said. "The problem is there are no back-up teams," he said, adding a nurse had to extend her shift to take care of the baby. "If we hadn't had the help from Kuujjuaq or nurses willing to work nearly 24 hours, we would have had at least two patients that would have died," says Rochette-Coulombe. Air Inuit only has one daytime team and one nighttime team in Puvirnituq to handle medevacs. Due to federal legislation, once pilots hit eight hours of flying time in a single day, they are grounded. But, health care staff are the ones to bear the brunt of that legislation when in an emergency situation, says Rochette-Coulombe. "They need to work harder and longer hours to stay with the patients because there is a delay with the planes," he said. "So they get frustrated, they get tired, they feel that they do their best, but in the end everything is blocked by the plane problem." Medevac flights rerouted The ongoing renovations to Puvirnituq's runway also mean Quebec aeromedical evacuation program's (EVAQ) air ambulances can't land in the community. Officials at the health centre did not answer Radio-Canada's questions on what measures they've taken to work around the issue. However, doctors have confirmed that patients have had to be flown to Kuujjuaq or Kuujjuarapik before finally getting on an air ambulance to Montreal. The 500-kilometre detour from Puvirnituq and Kuujjuaq adds more than two hours of travel. The renovations have also affected residents' ability to return to the community, says Lucy Qalingo, Puvirnituq's mayor. "I know a lot of people are affected by it, but it's for the long run for our youth … to have more access and to have more modernized equipment in our region," she said. "We have no choice but to face this for the time being." Qalingo added that the runway renovations would last until mid-September. Calls for better services Evan Wong is a surgeon and traumatologist with the McGill University Health Centre, and is part of the team that takes on patients from Nunavik. He's also studied the effects of delays to adequate health care for patients in the region. One study found that once a patient has suffered a serious trauma, their chances of clinical deterioration go up by four per cent for every hour of delay. Wong says the number of transfers from one type of transportation to another also increases risks. More resources should be dedicated to reducing the delays of getting patients from remote communities to appropriate hospital care, he says. This also echoes the findings of Québec coroner Julie-Kim Godin, who last year recommended that the province improve medevac services for remote communities after finding delays contributed to the death of a 61-year-old Salluit woman in 2022.
Globe and Mail
2 hours ago
- Globe and Mail
Polycythemia Vera Market Expands as FDA Fast Tracks New Treatments and Clinical Trials Show Promising Results
The 7MM Polycythemia Vera market size reached approximately USD 1,900 million in 2024 and is projected to grow significantly through 2034. Key players such as Incyte/Novartis, PharmaEssentia/AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck, Italfarmaco, Ionis Pharmaceutical, Silence Therapeutics, Perseus Proteomics, AbbVie, Johnson & Johnson Innovative Medicine, Mabwell (Shanghai) Bioscience and Disc Medicine, GluBio Therapeutics, and others are spearheading innovations. DelveInsight's report, titled ' Polycythemia Vera Market Insight, Epidemiology and Market Forecast -2034 ', provides a detailed assessment of historical and projected market trends from 2020 to 2034. The analysis encompasses epidemiology segmentation, treatment paradigms, emerging therapies, and competitive dynamics, offering stakeholders actionable insights into market opportunities and challenges. The report highlights how the anticipated introduction of targeted therapies and improved diagnostic tools will reshape the PV treatment landscape over the next decade. In 2024, the United States dominated the Polycythemia market, accounting for over 75% of the total market size, which amounts to USD 1.9 Billion across the 7MM. Among EU4 countries, Germany accounts for the maximum market size, while the United Kingdom occupies the bottom of the ladder in 2024. This trend is expected to continue reflecting disparities in treatment accessibility, Polycythemia Vera prevalence, and diagnostic rates across regions. Download the report to understand which factors are driving the Polycythemia Vera therapeutic market @ Polycythemia Vera Market Trends. The report also provides historical as well as forecasted PV epidemiology segmented by Total Prevalent Population of Polycythemia Vera, Prevalent Population of Polycythemia Vera Based on Symptoms, Gender-specific Prevalence of Polycythemia Vera, Prevalence of Polycythemia Vera by Gene Mutation, Prevalence of Polycythemia Vera Based on Risk, and Age-specific Prevalence of Polycythemia Vera in the 7MM. The report estimates that the 7MM had approximately 320,000 Polycythemia Vera cases in 2024, with numbers expected to rise steadily during the forecast period. Gender-specific data indicates that approximately 56% of the patient share in 7MM is attributed to males, whereas 44% are females. Additionally, across all races and ethnicities, the PV incidence is about 2.8 per 100,000 men and roughly 1.3 per 100,000 women. Discover evolving trends in Polycythemia Vera patient pool forecasts @ Polycythemia Vera Epidemiology Analysis. Recent Developments: In the latest financial statement, Incyte reported strong growth for Jakafi with net revenues of $773 million in Q4 2024 and $2.79 billion for the full year. In March 2025, Protagonist Therapeutics and Takeda announced positive topline results from the Phase 3 VERIFY study, where rusfertide met its primary and all secondary endpoints in treating polycythemia vera. These recent developments indicate positive momentum in the Polycythemia Vera treatment market. Rusfertide achieved a major milestone with the presentation of Phase 3 VERIFY trial results at the ASCO Annual Meeting in June 2025. The study met its primary endpoint and all key secondary endpoints, showing that rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups compared to placebo. In May 2025, the FDA granted Fast Track designation to givinostat, an orally administered histone deacetylase (HDAC) inhibitor for treating patients with polycythemia vera, highlighting givinostat's potential to make a meaningful difference. Learn more about the evolving trends in the Polycythemia Vera treatment market @ Polycythemia Vera Recent Developments. Polycythemia Vera management currently relies on a combination of treatments, including phlebotomy, cytoreductive agents such as hydroxyurea, and JAK inhibitors like JAKAFI (RUXOLITINIB) from Incyte/Novartis. Other notable medications used in the management of PV include BESREMi (PharmaEssentia/AOP Orphan Pharmaceuticals) and PEGASYS (pharmaand GmbH). Given its very different MoA compared to JAKAFI and BESREMi, rusfertide could become a viable alternative as an earlier line of therapy. In 2024, JAKAFI generated the highest revenue among these Polycythemia Vera therapies. While these therapies help manage symptoms and reduce thrombotic risks, they are associated with limitations including drug resistance, long-term toxicity, and inadequate control of disease progression. DelveInsight's report emphasizes that a significant number of patients experience suboptimal responses to existing treatments, highlighting a pressing need for novel mechanisms of action. The report highlights that the Polycythemia Vera pipeline features several investigational therapies across phases of development. Notable candidates include DIVESIRAN (Silence Therapeutics), PPMX-T003 (Perseus Proteomics), NAVITOCLAX (AbbVie), VAC85135 (Johnson & Johnson), 9MW3011/DISC-3405 (Mabwell), GLB-001 (GluBio Therapeutic) and others. Despite progress, challenges such as delayed diagnosis, treatment-related anemia, and lack of consensus on optimal monitoring strategies persist. DelveInsight's analysis identifies biomarker development and patient-centric drug delivery systems as key areas for innovation. Table of Contents 1. Key Insights 2. Report Introduction 3. Executive Summary 4. Polycythemia Vera Market Overview at a Glance 5. Epidemiology and Market Forecast Methodology 6. Key Events 7. Polycythemia Vera Background and Overview 8. Polycythemia Vera Treatment 9. Polycythemia Vera Epidemiology and Patient Population in the 7MM 10. Polycythemia Vera Patient Journey 11. Polycythemia Vera Marketed Drug 12. Polycythemia Vera Emerging Drugs 13. Polycythemia Vera: 7MM Analysis 14. Unmet needs 15. SWOT Analysis 16. KOL Views 17. Market Access and Reimbursement 18. Appendix 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight Related Reports Polycythemia Vera Pipeline Insight Polycythemia Vera Pipeline Insight provides comprehensive insights about the Polycythemia Vera pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Polycythemia Vera companies, including Silence Therapeutics, Ionis Pharmaceuticals, Perseus Proteomics, Kartos Therapeutics, and Disc Medicine among others. About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
CTV News
3 hours ago
- CTV News
Family of cyclist critically injured in Stittsville crash speaks out
L.A. Barrett, a former makeup artist at CTV Ottawa, speaks with CTV's Katie Griffin about Ghost, her adult child who remains in ICU after a serious collision.
